Alectinib in a patient with ALK-positive non-small lung cancer unable to swallow capsules

Introduction The treatment landscape of metastatic non-small-cell lung cancer (NSCLC) has changed dramatically in the last decade. Anaplastic lymphoma kinase (ALK) rearrangement has been a focus of interest since ALK inhibitors produced outstanding clinical results compared with chemotherapy with cy...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of oncology pharmacy practice 2023-07, Vol.29 (5), p.1283-1285
Hauptverfasser:	Ishiura, Yoshihisa, Nomura, Shosaku, Ishii, Yuka, Imai, Kai, Nakahama, Kahori, Sawai, Yusuke, Tamaki, Takeshi, Shimizu, Toshiki, Miyashita, Naoyuki, Ito, Tomoki
Format:	Artikel
Sprache:	eng
Schlagworte:	Capsules Carcinoma, Non-Small-Cell Lung - pathology Chemotherapy Cytotoxic agents Cytotoxicity Female Humans Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - pathology Metastases Metastasis Middle Aged Non-small cell lung carcinoma Oral administration Patients Piperidines - therapeutic use Protein Kinase Inhibitors - adverse effects Protein-tyrosine kinase Small cell lung carcinoma Swallowing
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!